FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045398464> ?p ?o ?g. }

• W2045398464 endingPage "607" @default.
• W2045398464 startingPage "600" @default.
• W2045398464 abstract "Because limited information exists regarding whether the rate or magnitude of PSA decline following brachytherapy predicts long-term clinical outcomes, we evaluated whether achieving a prostate-specific antigen (PSA) nadir (nPSA) <0.5 ng/mL following brachytherapy is associated with decreased PSA failure and/or distant metastasis.We retrospectively analyzed our database of early-stage prostate adenocarcinoma patients who underwent brachytherapy, excluding those receiving androgen-deprivation therapy and those with <2 years follow-up. Median and mean pretreatment PSA were 6 ng/mL and 7.16 ng/mL, respectively. By clinical stage, 775 were low risk (≤ T2a), 126 were intermediate risk (T2b), and 20 were high risk (>T2b). By Gleason score, 840 were low risk (≤ 6), 71 were intermediate risk (7), and 10 were high risk (>7). Patients were treated with brachytherapy only (I-125, n = 779, or Pd-103, n = 47), or brachytherapy + external-beam radiation therapy (n = 95). Median follow-up was 6.3 years. We noted whether nPSA <0.5 ng/mL was achieved and the time to achieve this nadir and tested for associations with pretreatment risk factors. We also determined whether this PSA endpoint was associated with decreased PSA failure or distant metastasis.Absence of high-risk factors in clinical stage (≤ T2b), Gleason score (≤ 7), and pretreatment PSA (≤ 20 ng/mL) was significantly associated with achieving nPSA <0.5 ng/mL. By Kaplan-Meier analysis, patients achieving nPSA <0.5 ng/mL had significantly higher long-term freedom from biochemical failure (FFBF) than nonresponders (5-year FFBF: 95.2 ± 0.8% vs. 71.5 ± 6.7%; p < 0.0005). Among responders, those who achieved nPSA <0.5 ng/mL in ≤ 5 years had higher FFBF than those requiring >5 years (5-year FFBF: 96.7 ± 0.7% vs. 80.8 ± 4.6%; p < 0.0005). On multivariate analysis, patients who achieved nPSA <0.5 ng/mL in ≤ 5 years had significantly higher FFBF than other patients.Pretreatment risk factors (clinical tumor stage, Gleason score, pretreatment PSA) strongly predict for patients achieving nPSA <0.5 ng/mL following brachytherapy, and this cohort had significantly higher long-term FFBF." @default.
• W2045398464 created "2016-06-24" @default.
• W2045398464 creator A5008857530 @default.
• W2045398464 creator A5012386908 @default.
• W2045398464 creator A5034991336 @default.
• W2045398464 date "2012-06-01" @default.
• W2045398464 modified "2023-09-30" @default.
• W2045398464 title "PSA Nadir of <0.5 ng/mL Following Brachytherapy for Early-Stage Prostate Adenocarcinoma is Associated With Freedom From Prostate-Specific Antigen Failure" @default.
• W2045398464 cites W1550436913 @default.
• W2045398464 cites W1974060176 @default.
• W2045398464 cites W1977382117 @default.
• W2045398464 cites W1978415948 @default.
• W2045398464 cites W1987603055 @default.
• W2045398464 cites W2001011706 @default.
• W2045398464 cites W2002791864 @default.
• W2045398464 cites W2020806183 @default.
• W2045398464 cites W2028639839 @default.
• W2045398464 cites W2047513095 @default.
• W2045398464 cites W2076630886 @default.
• W2045398464 cites W2087764509 @default.
• W2045398464 cites W2097462664 @default.
• W2045398464 cites W2103699030 @default.
• W2045398464 cites W2119991376 @default.
• W2045398464 cites W2126645707 @default.
• W2045398464 cites W2171210159 @default.
• W2045398464 cites W2460304404 @default.
• W2045398464 doi "https://doi.org/10.1016/j.ijrobp.2011.07.009" @default.
• W2045398464 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21985944" @default.
• W2045398464 hasPublicationYear "2012" @default.
• W2045398464 type Work @default.
• W2045398464 sameAs 2045398464 @default.
• W2045398464 citedByCount "34" @default.
• W2045398464 countsByYear W20453984642012 @default.
• W2045398464 countsByYear W20453984642013 @default.
• W2045398464 countsByYear W20453984642014 @default.
• W2045398464 countsByYear W20453984642015 @default.
• W2045398464 countsByYear W20453984642016 @default.
• W2045398464 countsByYear W20453984642017 @default.
• W2045398464 countsByYear W20453984642018 @default.
• W2045398464 countsByYear W20453984642019 @default.
• W2045398464 countsByYear W20453984642020 @default.
• W2045398464 countsByYear W20453984642021 @default.
• W2045398464 countsByYear W20453984642023 @default.
• W2045398464 crossrefType "journal-article" @default.
• W2045398464 hasAuthorship W2045398464A5008857530 @default.
• W2045398464 hasAuthorship W2045398464A5012386908 @default.
• W2045398464 hasAuthorship W2045398464A5034991336 @default.
• W2045398464 hasConcept C121608353 @default.
• W2045398464 hasConcept C126322002 @default.
• W2045398464 hasConcept C126894567 @default.
• W2045398464 hasConcept C141071460 @default.
• W2045398464 hasConcept C146357865 @default.
• W2045398464 hasConcept C151730666 @default.
• W2045398464 hasConcept C168563851 @default.
• W2045398464 hasConcept C203092338 @default.
• W2045398464 hasConcept C2776235491 @default.
• W2045398464 hasConcept C2777416452 @default.
• W2045398464 hasConcept C2777899217 @default.
• W2045398464 hasConcept C2778648096 @default.
• W2045398464 hasConcept C2780192828 @default.
• W2045398464 hasConcept C2781406297 @default.
• W2045398464 hasConcept C509974204 @default.
• W2045398464 hasConcept C71924100 @default.
• W2045398464 hasConcept C86803240 @default.
• W2045398464 hasConceptScore W2045398464C121608353 @default.
• W2045398464 hasConceptScore W2045398464C126322002 @default.
• W2045398464 hasConceptScore W2045398464C126894567 @default.
• W2045398464 hasConceptScore W2045398464C141071460 @default.
• W2045398464 hasConceptScore W2045398464C146357865 @default.
• W2045398464 hasConceptScore W2045398464C151730666 @default.
• W2045398464 hasConceptScore W2045398464C168563851 @default.
• W2045398464 hasConceptScore W2045398464C203092338 @default.
• W2045398464 hasConceptScore W2045398464C2776235491 @default.
• W2045398464 hasConceptScore W2045398464C2777416452 @default.
• W2045398464 hasConceptScore W2045398464C2777899217 @default.
• W2045398464 hasConceptScore W2045398464C2778648096 @default.
• W2045398464 hasConceptScore W2045398464C2780192828 @default.
• W2045398464 hasConceptScore W2045398464C2781406297 @default.
• W2045398464 hasConceptScore W2045398464C509974204 @default.
• W2045398464 hasConceptScore W2045398464C71924100 @default.
• W2045398464 hasConceptScore W2045398464C86803240 @default.
• W2045398464 hasIssue "2" @default.
• W2045398464 hasLocation W20453984641 @default.
• W2045398464 hasLocation W20453984642 @default.
• W2045398464 hasOpenAccess W2045398464 @default.
• W2045398464 hasPrimaryLocation W20453984641 @default.
• W2045398464 hasRelatedWork W1980188241 @default.
• W2045398464 hasRelatedWork W1995422080 @default.
• W2045398464 hasRelatedWork W2038565121 @default.
• W2045398464 hasRelatedWork W2127440557 @default.
• W2045398464 hasRelatedWork W2148869351 @default.
• W2045398464 hasRelatedWork W2165532162 @default.
• W2045398464 hasRelatedWork W2373651588 @default.
• W2045398464 hasRelatedWork W2897445903 @default.
• W2045398464 hasRelatedWork W3129209394 @default.
• W2045398464 hasRelatedWork W4281788288 @default.
• W2045398464 hasVolume "83" @default.
• W2045398464 isParatext "false" @default.

• next